Cadrenal Therapeutics, Inc.
CVKD
$5.42
$0.234.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.15% | 26.77% | 4.63% | 8.17% | -73.91% |
| Total Depreciation and Amortization | 50.00% | 0.00% | -92.73% | 1,275.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.33% | -20.11% | 7.98% | -28.09% | 154.48% |
| Change in Net Operating Assets | 198.76% | -400.00% | 103.56% | -183.14% | 1,842.80% |
| Cash from Operations | -9.03% | 22.10% | 34.91% | -159.61% | 18.65% |
| Capital Expenditure | 100.00% | -- | 100.00% | 49.23% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | 100.00% | 49.23% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 352.65% | -48.34% | -35.58% | -41.40% | 114.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -963.20% | 44.11% | 25.32% | -102.16% | 3,758.16% |
| Cash from Financing | 319.14% | -48.56% | -36.02% | -73.56% | 387.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.63% | 3.10% | 34.18% | -147.43% | 939.74% |